Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The terms refer only to a partner pharmacy network, and the product and sale pages to licensed U.S. pharmacies. 1 more criterion also fails; see the table below.
At a glance
Freya MedsTelehealth service
6/8criteria passed
Price
Semaglutide from $150 a month on an annual plan (regular $297 month to month), tirzepatide from $249
Sells
compounded semaglutide, compounded tirzepatide, and 2 more
Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.
A telehealth platform selling compounded semaglutide and tirzepatide on monthly, quarterly and annual plans, a PT-141 and oxytocin tablet for women and NAD+ injections, with prescribing by doctors at partner physician practices. Care starts with a short online health assessment, and no pharmacy is named.
Freya Meds' important safety information for compounded semaglutide page; Freya Meds' important safety information for compounded tirzepatide page; Freya Meds' GLP-1 sale page
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSThe answers say a licensed clinician reviews each medical history and prescribes only when GLP-1 treatment is appropriate and safe, and the terms say care comes from providers employed or contracted by independent partner physician practices.Source: Freya Meds' website; Freya Meds' terms and conditions.
S2PASSThe home page puts a two-minute health assessment first and a doctor's review before any prescription. The answers say payment for the monthly plan is taken before the clinician sets the dose, and the refund policy refunds a charge in full when no prescription is issued.Source: Freya Meds' website; Freya Meds' refund policy; Freya Meds' treatments page.
S3FAILNo filling pharmacy is named. The terms refer only to a partner pharmacy network, and the product and sale pages to licensed U.S. pharmacies.Source: Freya Meds' terms and conditions; Freya Meds' GLP-1 sale page.
S4PASSThe safety information pages for compounded semaglutide and compounded tirzepatide, and the sale page, state that compounded medications are not FDA-approved and are not reviewed for safety, effectiveness or manufacturing quality.Source: Freya Meds' important safety information for compounded semaglutide page; Freya Meds' important safety information for compounded tirzepatide page; Freya Meds' GLP-1 sale page.
S5FAILNo certificate of analysis or lot document is published. The tirzepatide safety page says the medication is third-party tested for purity, with no document behind the claim.Source: Freya Meds' important safety information for compounded tirzepatide page; Freya Meds' semaglutide page.
S6PASS30 N Gould St, Suite R, Sheridan, WY 82801, printed in the privacy policy and the terms, which name Freya Meds Inc.Source: Freya Meds' privacy policy; Freya Meds' terms and conditions; Freya Meds' refund policy.
S7PASSCompounded semaglutide at $150 a month on an annual plan, $250 on a quarterly plan or $297 month to month, and compounded tirzepatide at $249, $333 or $390, on the pricing page; the tirzepatide product page prints the quarterly rate as $332. A sale page shows $297 struck through beside $150. The PT-141 and oxytocin tablet starts at $99.70 a month.Source: Freya Meds' pricing page; Freya Meds' semaglutide page; Freya Meds' tirzepatide page; Freya Meds' olympus page.
S8PASSNo FDA warning letter names Freya Meds or Freya Meds Inc., and no action has halted the business.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, Olympus (PT-141 with oxytocin tablet), NAD+ injections.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.